Company Name: Ultragenyx Pharmaceutical Inc.   

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company is engaged in the development of therapies designed to treat rare/ultra-rare diseases. The company’s focus is on serious genetic diseases. The company’s pipeline includes product candidates designed to treat a variety of conditions including:

  • Galactosialidosis
  • Glucose Transporter 1 Deficiency (Glut1 DS)
  • GNE Myopathy (GNEM)
  • Long-Chain Fatty Acid Oxidation Disorders (FAOD)
  • Mucopolysaccharidosis 7 (MPS 7)
  • Tumor-Induced Osteomalacia (TIO)
  • X-Linked Hypophosphatemia (XLH)

Ticker Symbol: RARE (NASDAQ)

Company Website: www.ultragenyx.com

Social Media: Ultragenyx Pharmaceutical LinkedIn Page

Headquarters: Novato, California